Business
Amgen Announces New Data Highlighting Global Trends In Hip Fracture Incidence And Treatment
Real-World Data Reinforces Hip Fracture as a Significant Public Health Issue Globally, With Low Use of Pharmacologic Interventions Results Presented as a
About this update from Amgen Inc.
[{"type":"text","content":"Real-World Data Reinforces Hip Fracture as a Significant Public Health Issue Globally, With Low Use of Pharmacologic Interventions\n Results Presented as a Late-Breaking Abstract at the American Society for Bone and Mineral Research 2021 Annual Meeting (ASBMR)\n\n\nTHOUSAND OAKS, Calif., Oct. 4, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from real-world data in Asia, Europe, Oceania, and North and South America on the temporal trends in hip fracture incidence, and in post-fracture pharmacological treatment intervention. The study, presented as a late-breaking abstract at the American Society for Bone and Mineral Research 2021 Annual Meeting (ASBMR), is titled \"Hip Fractures: Initial Report of Trends in Incidence, Treatment, and Mortality In Multiple Countries Using a Common Analytical Platform.\" The results of the study reveal that hip fracture remains a significant public health issue across the globe, and that the effects of aging populations and suboptimal pharmacological treatment may contribute to an increasing burden of osteoporosis.i \n\"Hip fractures represent a major public health crisis, but previously available reports on incidence are based on decades old data for some regions,\" said Darryl Sleep, M.D., senior vice president of Global Medical and chief medical officer at Amgen. \"We are excited to present the latest global data on hip fractures, which uses a unified methodology that makes it possible to provide updated incidence, as well as valuable insights on the risk factors and next steps in the treatment of osteoporosis.\"\nThis study, led by the University of Hong Kong, was funded by Amgen and includes Amgen authors. This initial report, inclusive of years 2005 and 2018, is based on thirteen data sources from Australia, Canada, Germany, Hong Kong, Italy, the Netherlands, New Zealand, South Korea, Spain, Taiwan, United Kingdom, and two systems (Medicare and Optum's de–identified Clinformatics® Data Mart Database) from the United States.i The change in age-standardized hip fracture incidence varied from -2.1% to +2.3% per year across all data sources (HK, -2.1%; UK, -1.3%; TW, -1.8%; IT, -1.4%; Spain, -1.1%; USM, -1.1%; Canada, -0.9%; NZ, -0.8%; USO, -0.2%; AU, +0.2%; GE, +0.8%; SK, +0.8%; NL, +2.3%); those data sources with full population coverage show the absolute number of hip fractur...